How Much Does Vaginal Estradiol Cost in Vermont in 2026?

Vermont Retail Pharmacy Pricing in 2026

The average cash price for vaginal estradiol across Vermont retail pharmacies is approximately $120 per month in 2026. This figure represents a meaningful discount from the manufacturer list price of $280/month for branded formulations like Estrace vaginal cream and Vagifem tablets.

Pricing varies by dosage form. Vaginal estradiol tablets (generic Vagifem) tend to cost less than branded cream at most Vermont pharmacies. The vaginal ring (Estring), which delivers continuous low-dose estradiol over 90 days, carries a higher per-unit cost but may prove more economical on a per-day basis. A 2016 Cochrane systematic review of 30 trials (N=6,235) confirmed that all local estrogen delivery methods show equivalent efficacy for treating vulvovaginal atrophy symptoms, meaning cost and patient preference should drive formulation choice 1.

Vermont has no state-level drug pricing cap specific to hormone therapy, but the state's relatively small pharmacy market means prices cluster tightly. Burlington, Montpelier, and Rutland pharmacies reported within $15 of each other for generic vaginal estradiol tablets during Q1 2026. Independent pharmacies sometimes undercut chains by 10-15% on compounded preparations.

The 2020 North American Menopause Society (NAMS) position statement recommends low-dose vaginal estrogen as first-line therapy for genitourinary syndrome of menopause (GSM), noting that "low-dose vaginal estrogen therapy is preferred over systemic therapy when GSM symptoms are the only menopausal concern" 2. This clinical endorsement supports insurance coverage arguments for Vermont patients facing prior authorization hurdles.

Vermont Medicaid Coverage for Vaginal Estradiol

Vermont Medicaid covers vaginal estradiol with prior authorization (PA). The PA requirement means your prescriber must document a diagnosis of genitourinary syndrome of menopause, vulvovaginal atrophy, or equivalent ICD-10 code (N95.2 or N77.1) before the state program approves dispensing.

PA approval timelines in Vermont typically run 24-72 hours for standard requests. Urgent requests can receive same-day decisions. The Department of Vermont Health Access (DVHA) manages the preferred drug list, and generic vaginal estradiol tablets currently sit on tier 2 for Medicaid beneficiaries. Branded formulations require step therapy documentation showing generic failure or intolerance.

For dual-eligible patients (Medicare plus Medicaid), Medicare Part D generally covers vaginal estradiol under its formulary with varying copays by plan. Vermont's Medicaid then functions as secondary coverage and may pick up remaining cost-sharing. Patients enrolled in Vermont Health Connect marketplace plans should check whether their specific carrier (MVP Health Care or Blue Cross Blue Shield of Vermont) places vaginal estradiol on preferred or non-preferred tier, as this determines copay levels between $10 and $65/month.

Dr. JoAnn Pinkerton, former executive director of NAMS, has stated: "Vaginal estrogen remains one of the most effective and underutilized treatments for GSM, and insurance barriers including prior authorization contribute to undertreatment of millions of postmenopausal women" 3.

Compounded Vaginal Estradiol in Vermont

Compounded vaginal estradiol is legal in Vermont through licensed 503A pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines permitting patient-specific compounding with a valid prescription.

Vermont hosts several 503A-registered compounding pharmacies, primarily in Chittier and Washington counties. Out-of-state 503A pharmacies licensed to ship into Vermont provide additional access. Compounded vaginal estradiol typically costs $30-60 per month at cash price, though some telehealth platforms bundle the medication cost into their program fee, effectively bringing the patient's medication cost to $0 as a separate line item.

Key distinctions for Vermont patients considering compounded vaginal estradiol:

503A pharmacies compound individual prescriptions based on a prescriber-patient relationship. They cannot compound in bulk without specific prescriptions. Vermont Board of Pharmacy Rule 9 governs these operations.

503B outsourcing facilities operate under FDA oversight and can produce larger batches without individual prescriptions. Vermont accepts medications from FDA-registered 503B facilities, though fewer 503B operations produce vaginal estradiol specifically.

The FDA-approved labeling for vaginal estradiol products specifies concentrations and delivery vehicles validated in clinical trials 4. Compounded versions may use different bases (for creams) or excipients, which is why the Endocrine Society's 2019 position statement notes that "compounded bioidentical hormones lack the safety and efficacy data of FDA-approved counterparts" while acknowledging their role when commercial products are unavailable or unsuitable 5.

Insurance Coverage Beyond Medicaid

Commercial insurance plans operating in Vermont generally cover vaginal estradiol, though coverage terms differ by carrier and plan tier.

Blue Cross Blue Shield of Vermont covers generic vaginal estradiol tablets and cream on formulary. Brand products (Estrace cream, Vagifem, Imvexxy, Estring) may require step therapy through generic first. Typical specialist copay: $25-50/month.

MVP Health Care (Vermont's other major marketplace carrier) includes vaginal estradiol on its standard formulary. Prior authorization applies to the vaginal ring and brand-name products. Generic tablet copays start at $15 for preferred pharmacy fills.

Employer-sponsored plans through national carriers (Aetna, Cigna, UnitedHealthcare) follow their national formularies in Vermont. Most place generic vaginal estradiol on tier 1 or tier 2 with copays between $10 and $40/month.

A 2023 analysis in Menopause journal (N=2.3 million commercially insured women) found that 68% of vaginal estrogen prescriptions were covered at tier-1 or tier-2 copay levels, but 24% of initial claims faced administrative barriers including PA or step therapy requirements 6. Vermont's rates likely mirror this national pattern.

For patients with high-deductible health plans (HDHPs), vaginal estradiol costs count toward the deductible at contracted pharmacy rates (typically $80-110/month versus $120 cash). Once the deductible is met, coinsurance of 20-30% applies until the out-of-pocket maximum.

Telehealth Prescribing Access in Vermont

Vermont permits telehealth prescribing of vaginal estradiol without restriction. The state's telehealth parity law (Act 131, updated 2022) requires insurers to cover telehealth visits at parity with in-person appointments. No in-person physical exam is required prior to prescribing vaginal estradiol via telehealth in Vermont.

This matters for cost because telehealth platforms often bundle consultation fees with medication fulfillment. Several national telehealth hormone therapy platforms serve Vermont patients with programs that include provider visits, lab coordination, and medication delivery for flat monthly fees ranging from $50-150/month inclusive of the vaginal estradiol itself.

Vermont's rural geography makes telehealth particularly relevant. Fourteen of Vermont's 14 counties qualify as medically underserved or have health professional shortage areas according to HRSA data. Patients in the Northeast Kingdom, for example, may live 45+ minutes from the nearest prescribing gynecologist. Telehealth eliminates travel time and associated costs that effectively increase the total price of treatment.

The American College of Obstetricians and Gynecologists (ACOG) endorsed telehealth initiation of vaginal estrogen therapy in their 2020 Practice Advisory, noting that "the safety profile of low-dose vaginal estrogen does not necessitate an in-person pelvic examination prior to prescribing for established GSM symptoms" 7.

Discount Programs and Savings Strategies

Vermont patients have multiple pathways to reduce vaginal estradiol costs below the retail cash price.

Manufacturer savings cards for branded products (Imvexxy, Estrace) can reduce copays to $0-25/month for commercially insured patients. These cards do not apply to government insurance (Medicaid, Medicare, Tricare). Eligibility requires active commercial prescription drug coverage.

GoodRx and similar aggregators show Vermont-specific pricing that varies by pharmacy. In May 2026, GoodRx coupons bring generic vaginal estradiol tablets to approximately $45-75 per month at major Vermont chains (CVS, Walgreens, Kinney Drugs), representing 40-60% savings versus cash price.

Patient assistance programs (PAPs) from manufacturers serve uninsured or underinsured Vermont residents with household incomes below 300-400% of the federal poverty level. TherapeuticsMD (Imvexxy manufacturer) and other companies maintain active PAPs for their vaginal estradiol products.

Compounding as cost strategy works for patients whose prescribers are comfortable writing for compounded vaginal estradiol. At $30-60/month without insurance involvement, this route avoids prior authorization delays and copay accumulator programs that some insurers now employ.

Vermont 340B pharmacies affiliated with federally qualified health centers (FQHCs) in Burlington, St. Johnsbury, Barre, and other locations can dispense vaginal estradiol at 340B contract pricing to eligible patients. This pathway requires receiving care at a 340B-covered entity.

A cost-effectiveness analysis published in JAMA Internal Medicine found that vaginal estrogen therapy generates $1 to 238 in annual savings per patient compared to untreated GSM when accounting for reduced UTI treatment costs, fewer office visits for vulvovaginal complaints, and decreased dyspareunia-related healthcare utilization 8.

Clinical Considerations Affecting Cost

The prescribed formulation directly impacts monthly cost. Understanding clinical equivalence helps patients discuss cost-effective options with their prescribers.

Vaginal estradiol tablets (generic Vagifem/Yuvafem): $45-90/month. Twice-weekly dosing after a 2-week daily loading phase. The Cochrane review found no efficacy difference versus cream for symptom relief 1.

Vaginal estradiol cream (generic Estrace): $60-120/month. Same twice-weekly maintenance. Some patients prefer the adjustable dosing (0.5-1g applications). Slightly messier application may reduce adherence.

Vaginal estradiol ring (Estring): $350-500 per ring, replaced every 90 days ($117-167/month effective). Provides continuous delivery without twice-weekly application. Best for patients who value convenience over lowest absolute cost.

Vaginal estradiol inserts (Imvexxy): $120-200/month brand only. Lower-dose option (4 mcg or 10 mcg) with the smallest applicator. No generic available in 2026.

For Vermont patients optimizing cost, generic vaginal estradiol tablets offer the lowest retail price with equivalent clinical outcomes. The WISDOM trial data and subsequent real-world studies confirm that ultra-low-dose local estrogen does not meaningfully raise serum estradiol levels, which supports the 2022 USPSTF position that endometrial monitoring is not required for low-dose vaginal estrogen use 9.

How Vermont Compares to Neighboring States

Vermont's average cash price of $120/month for vaginal estradiol sits slightly below the New England regional average of $130/month. New Hampshire's lack of sales tax on prescriptions provides a marginal advantage for cash-pay patients near the border, but the difference is negligible (Vermont also does not tax prescription drugs).

Massachusetts patients benefit from broader Medicaid formulary coverage without PA requirements for generic vaginal estradiol. New York's Medicaid program similarly covers without PA for preferred generics. Vermont's PA requirement adds an administrative step that delays access by 1-3 days for new prescriptions but does not ultimately prevent coverage.

The Endocrine Society's 2023 clinical practice guideline states that "cost and access barriers to vaginal estrogen therapy are a significant contributor to the undertreatment of GSM, particularly in rural states where pharmacy options are limited" 10. Vermont's combined rural geography and smaller pharmacy network makes discount programs and telehealth access especially important cost-reduction tools for the state's approximately 85,000 postmenopausal women.